Sanofi-Aventis Vietnam Co., Ltd. is seeking to strengthen cooperation with the Ministry of Health (MoH) to increase access to ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

Dr Sara Brenner, the FDA's principal deputy commissioner, has paused the approval process for Novavax's Covid-19 vaccine by requesting additional data.Source: Novavax.This intervention coincides with ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...